Incyte Corporation (BIT:1INCY)

Market Cap	9.91B
Revenue (ttm)	4.10B
Net Income (ttm)	31.50M
Shares Out	n/a
EPS (ttm)	0.14
PE Ratio	314.46
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	130
Average Volume	58
Open	50.06
Previous Close	51.48
Day's Range	50.06 - 51.16
52-Week Range	47.33 - 79.44
Beta	n/a
RSI	28.57
Earnings Date	Apr 29, 2025

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhib...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1991
• Employees: 2,617
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1INCY

Financial Performance

In 2024, Incyte's revenue was $4.24 billion, an increase of 14.76% compared to the previous year's $3.70 billion. Earnings were $32.62 million, a decrease of -94.54%.

Financial numbers in USD